Thatch Valuation 2026: $1B After a $108M Series C, as ICHRA Becomes the CHOICE Arrangement

Thatch, an employer-funded health benefits platform, reached a $1 billion valuation on September 15, 2026, after closing a $108 million Series C — up from $410 million just 17 months earlier, and landing days after regulators renamed the underlying benefit type it runs on.

The round, reported by TechCrunch and Fierce Healthcare on September 15, 2026, was led by General Catalyst and Index Ventures, with participation from The General Partnership, Andreessen Horowitz, ADP Ventures, Paychex, Eli Lilly, Scale Venture Partners, QuantumLight, SemperVirens, Quiet Capital, and Avid Ventures. The timing is notable: on September 3, 2026, the Centers for Medicare & Medicaid Services and the Small Business Administration jointly rebranded ICHRA as the CHOICE Arrangement, the exact benefit category Thatch's entire product is built around.

What Is Thatch's Valuation and What Does It Actually Sell?

Thatch's $1 billion valuation, set September 15, 2026, prices a platform that administers ICHRA — an employer-funded arrangement that gives workers tax-free money to buy their own individual health insurance plan, instead of enrolling everyone in one company-selected group plan. Founded in 2021 by Chris Ellis and Adam Stevenson, San Francisco-based Thatch now says, in its own funding announcements, that more than 5,000 employers use its platform, including Jersey Mike's and Smoothie King, and that annual recurring revenue grew roughly 7x over the past year as employers looked for ways to manage rising group health insurance costs.

Thatch at a Glance

Sources: TechCrunch and Fierce Healthcare (Sept 15, 2026); TechFundingNews aggregate total-funding figure.

Thatch's Funding History, Round by Round

Thatch's earlier rounds set up that jump: a pre-seed and seed round of just over $6 million closed in February 2023, led by a16z and GV with participation from Lux Capital, Quiet Capital, Not Boring Capital, and BrightEdge; a $38 million Series A followed in 2024; then the $40 million, $410 million-valuation Series B in April 2025 led by Index Ventures. Across all four rounds, Thatch has now raised roughly $193 million.

Why Did Regulators Rename ICHRA to the CHOICE Arrangement?

The Individual Coverage Health Reimbursement Arrangement, created under the first Trump administration's 2019 rules, lets employers of any size fund tax-advantaged accounts employees use to buy individual health coverage rather than joining a single group plan. On September 3, 2026, CMS and the SBA jointly rebranded it as the "CHOICE Arrangement" — Custom Health Option and Individual Care Expenses — as part of a push to promote the model to small businesses; the underlying tax and eligibility rules did not change, and existing ICHRA plan documents and payroll setups remain valid. The number of people covered by ICHRA-type plans surpassed 500,000 at the start of 2026, according to industry tracking cited by Becker's Payer Issues, still a small fraction of the roughly 150 million Americans on employer-sponsored group plans, but growing off a low base as more employers look for an alternative to annual group-premium increases.

Where the Thesis Could Break

A rebrand from a federal agency is a tailwind, not a moat — it doesn't stop competitors like Remodel Health, Venteur, or Take Command from selling ICHRA administration under the same new CHOICE Arrangement name, and Thatch's $1 billion valuation assumes it keeps winning share in a category it didn't invent and can't exclusively own. Neither Thatch's Series B nor Series C disclosed actual revenue alongside the valuation, so the "~7x ARR growth" figure, while a real number from the company's own CEO, has no disclosed base to size it against — 7x growth off a small starting revenue base is a very different story from 7x growth off a large one. ICHRA adoption also still covers a small fraction of the employer health insurance market, and a shift in federal health policy could alter the tax treatment that makes the whole category attractive to employers in the first place.

The Bottom Line

Thatch's path from a $6 million seed in February 2023 to a $1 billion valuation in September 2026 tracks a real regulatory tailwind — rising group health premiums pushing employers toward defined-contribution alternatives — landing in the same week the federal government gave that alternative a consumer-friendly new name. Whether Thatch's specific valuation holds up depends on ARR figures the company hasn't disclosed, but the underlying demand signal, 500,000-plus people now on ICHRA-type plans and climbing, is independently verifiable and real.